Unibest

Pharmaceutical intermediates

Belzutifan Intermediates

3 pharmaceutical intermediates for Belzutifan. Indication: Hippel-Lindau syndrome; renal cell carcinoma; hemangioblastoma; pancreatic neuroendocrine tumor; central nervous system tumor; neuroblastoma.

提交项目All intermediates

About Belzutifan

Originator
Peloton Therapeutics Inc
Indication
Hippel-Lindau syndrome; renal cell carcinoma; hemangioblastoma; pancreatic neuroendocrine tumor; central nervous system tumor; neuroblastoma
Approved Date
08/13/2021
NCE Patent
08/13/2026
DS/DP
09/05/2034

Available intermediates

3 intermediates currently listed for Belzutifan. Request specifications, documentation or a quotation for any item below.

Belzutifan intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
3-fluoro-5-((7-(methylsulfonyl)-1-oxo-2,3-dihydro-1H-inden-4-yl)oxy)benzonitrile1672665-55-2//
(R)-3-Fluoro-5-((3-hydroxy-7-(methylsulfonyl)-1-oxo-2,3-dihydro-1H-inden-4-yl)oxy)benzonitrile2738675-96-0 //
Fluoro-2,3-dihydro-7-(methylsulfonyl)-1H-inden-1-one1672665-29-0 //

Other programs under B

Baloxavir MarboxilBaricitinibBDTX-1535Bedaquiline FumarateBelumosudil mesylateBempedoic acidBeraprost SodiumBictegravir

Building toward Belzutifan?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →